lazertinib mesylate hydrate
(la-ZER-tih-nib MEH-zih-layt HY-drayt)
A drug used with amivantamab to treat adults with non-small cell lung cancer that has spread to other parts of the body or cannot be removed by surgery and has certain mutations (changes) in the EGFR gene. Lazertinib mesylate hydrate blocks certain proteins made by the mutated EGFR gene, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called Lazcluze.